Technical Analysis for CRIS - Curis, Inc.

Grade Last Price % Change Price Change
grade B 2.14 -0.93% -0.02
CRIS closed down 0.93 percent on Thursday, October 17, 2019, on 36 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average.

Earnings due: Oct 30

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical CRIS trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Support Bullish -0.93%
Stochastic Buy Signal Bullish -0.93%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.93%
Inside Day Range Contraction -0.93%
Oversold Stochastic Weakness -0.93%
MACD Bearish Centerline Cross Bearish 2.39%

Older signals for CRIS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Curis, Inc. engages in the research, development, and commercialization of cancer therapeutics. Its principal product is Erivedge capsule for treatment of adults with basal cell carcinoma (BCC) that has spread to other parts of the body or that has come back after surgery. The company also develops Erivedge, which is in phase II clinical trial for the treatment of operable nodular BCC; CUDC-427, a small molecule that has completed phase I clinical trial to promote cancer cell death in breast cancer and other solid tumors, and hematological cancers; and CUDC-907, a small molecule, which is in phase I clinical trial for the treatment of advanced lymphoma and multiple myeloma. In addition, it develops CUDC-101 that has completed phase I dose escalation clinical trial for the treatment of refractory solid tumors; and phase I expansion trial for the treatment of breast, gastric, head and neck, liver, or non-small cell lung cancers. Further, the company develops Debio 0932 that is in phase Ib expansion study for the treatment of solid tumors; and in a phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. It has collaborations with Genentech, Inc. for the development of Erivedge; and Debiopharm S.A. for the development and commercialization of Debio 0932. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Cancer Drugs Surgery Solid Tumors Drug Discovery Breast Cancer Multiple Myeloma Cancer Therapeutics Hematological Cancers Protein Kinase Inhibitors Phosphoinositide 3 Kinase Inhibitor Advanced Non Small Cell Lung Cancer Refractory Solid Tumors
Is CRIS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.9
52 Week Low 0.6
Average Volume 120,811
200-Day Moving Average 1.731
50-Day Moving Average 2.0866
20-Day Moving Average 2.258
10-Day Moving Average 2.156
Average True Range 0.1524
ADX 24.15
+DI 11.347
-DI 21.5692
Chandelier Exit (Long, 3 ATRs ) 2.0928
Chandelier Exit (Short, 3 ATRs ) 2.4572
Upper Bollinger Band 2.5618
Lower Bollinger Band 1.9542
Percent B (%b) 0.31
BandWidth 26.908769
MACD Line -0.0061
MACD Signal Line 0.0169
MACD Histogram -0.023
Fundamentals Value
Market Cap 307.9 Million
Num Shares 144 Million
EPS -0.50
Price-to-Earnings (P/E) Ratio -4.28
Price-to-Sales 27.52
Price-to-Book 24.84
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.27
Resistance 3 (R3) 2.26 2.21 2.25
Resistance 2 (R2) 2.21 2.18 2.21 2.24
Resistance 1 (R1) 2.18 2.16 2.15 2.18 2.23
Pivot Point 2.13 2.13 2.11 2.13 2.13
Support 1 (S1) 2.09 2.09 2.07 2.10 2.05
Support 2 (S2) 2.04 2.07 2.04 2.04
Support 3 (S3) 2.01 2.04 2.03
Support 4 (S4) 2.01